



FOR IMMEDIATE RELEASE

Press Contact: Mike Beyer

Ritz Communications

773-463-4211 (office)

312-961-2502 (mobile)

mike.beyer@ritzcommunications.com

**Metabolic Solutions Development Company, LLC to present at  
Windhover's 6th annual Therapeutic Area Partnerships meeting**

KALAMAZOO, Mich., November 30, 2011 - Metabolic Solutions Development Company, LLC, (MSDC) announced today its' lead compound MSDC - 0602, a novel insulin sensitizer, will be featured as part of Windhover's 2011 Top 10 Cardiovascular/Metabolic Diseases Projects to Watch. Windhover's 6th Annual Therapeutic Area Partnerships takes place Nov. 30 - Dec. 2 at the Westin Copley Place in Boston.

MSDC Chief Executive Officer Stephen Benoit will present on MSDC and the company's clinical development program at 4:30 p.m. on Thursday, Dec. 1.

MSDC is a drug discovery and development company investigating novel molecular targets and new therapies for metabolic diseases associated with mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.

MSDC-0602 is a novel insulin sensitizer that is selective for a molecular target, mTOT, a novel mitochondrial target, which functions as a "switch" connecting mitochondrial metabolism to important cell functions. In a recently completed Phase 2a study in patients diagnosed with type 2 diabetes, MSDC-0602 was shown to achieve significant glucose control and increase insulin sensitivity in a PPAR-independent manner.

**About Metabolic Solutions Development Company**

Metabolic Solutions Development Company ([www.msdrx.com](http://www.msdrx.com) <<http://www.msdrx.com>> ) is a drug discovery and development company investigating novel molecular targets and new therapies for metabolic diseases associated with mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised more than \$55 million to support development of its lead compounds MSDC-0160 and MSDC-0602.